At Synagenix, we are at the forefront of biotechnological innovation, dedicated to conquering neurodegenerative diseases through cutting-edge gene editing technology to provide neural rejuvenation. Our mission is to revolutionize the treatment of conditions like Alzheimer's, Parkinson's, and ALS.
We envision a future where neurodegenerative diseases are no longer life sentences. Our research focuses on utilizing a novel gene-editing platform to improve the utilization of stem cell transplants, in order to develop precise, effective treatments that can halt or reverse the progression of neural disease.
Our approach allows us to engineer stem cell therapies with unprecedented accuracy, offering hope for neural treatments that are both highly effective and minimally invasive.
Company Details
- Founded
- -
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Keywords
- New York.
Synagenix Questions
Synagenix's LinkedIn profile is https://www.linkedin.com/company/synagenix
Synagenix's industry is
Biotechnology Research
Synagenix's top competitors are
Leerink Partners,
Syridex Bio,
Beacon Legacy Partners,
Heritage Growth Partners Llc,
Greencove Capital Partners,
Indigo Prospect,
Qcap Group,
Gumshoe,
Apis Capital Advisors, Llc,
Aquilo Partners, L.p..
Synagenix's categories are Biotechnology Research
Synagenix's founding year is 2023
